Introduction
============

Intervertebral disc degeneration (IDD) is one of the major causes of lower back pain and spinal degenerative diseases. Globally, the point prevalence of lower back pain was reported to be 9.4%, which ranked the highest regarding the number of years living with the condition ([@b1-mmr-19-03-2164]). Recently, the morbidity from spinal degenerative diseases has rapidly increased with the aging of the population; at present, therapies mainly focus on alleviating clinical symptoms rather than restoring the underlying pathophysiological processes. Therefore, further investigation into IDD is urgently required ([@b2-mmr-19-03-2164]).

Previous studies demonstrated that nucleus pulposus cell (NPC) apoptosis serves a significant role in the occurrence and development of IDD ([@b3-mmr-19-03-2164]--[@b6-mmr-19-03-2164]). The apoptosis of NPCs initiates degenerative cascades in the aging nucleus pulposus (NP), and leads to structural and mechanical instability of the intervertebral disc ([@b7-mmr-19-03-2164],[@b8-mmr-19-03-2164]). Therefore, the anti-apoptotic targeting of NPCs by molecular or cellular therapies in the intervertebral disc via percutaneous puncture may delay or reverse the process of IDD.

Noncoding RNAs, including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), regulate gene expression in numerous cells, and have been demonstrated to be highly involved in IDD ([@b9-mmr-19-03-2164]). In NPCs, lower levels of miR-155 expression promoted Fas-mediated apoptosis by targeting Fas-associated protein with death domain and caspase-3 ([@b10-mmr-19-03-2164]), and decreased the amount of aggrecan and collagen type II via matrix metalloproteinase (MMP)-16 upregulation ([@b11-mmr-19-03-2164]). Additionally, increasing evidence has suggested the important roles of lncRNAs in IDD, which may serve as novel therapeutic targets for degenerative spinal diseases ([@b12-mmr-19-03-2164],[@b13-mmr-19-03-2164]). In addition, the sophisticated crosstalk between miRNAs and lncRNAs also suggests their notable functions of coordinating gene expression in a multitude of processes ([@b14-mmr-19-03-2164]); however, investigations into the interactions between miRNAs and lncRNAs in IDD are scarce.

The growth arrest-specific transcript 5 (GAS5) gene was firstly isolated by Schneider *et al* ([@b15-mmr-19-03-2164]) in growth-inhibited cells in 1988 and was classified as a non-protein-coding multiple small nucleolar RNA that serves a major growth-inhibiting role ([@b16-mmr-19-03-2164]). Numerous studies reported that GAS5 was pivotal in promoting apoptosis and suppressing cell proliferation in mammals ([@b17-mmr-19-03-2164]--[@b19-mmr-19-03-2164]); however, the function of GAS5 in IDD remains unknown. In the present study, lncRNAs targeted by miR-155 were screened and the lncRNA GAS5 was predicted to be a target of miR-155 in NPCs. Therefore, the functional mechanism of GAS5 was investigated to reveal the effects of GAS5 on primary human NPC apoptosis. Interestingly, GAS5 overexpression promoted NPC apoptosis via B cell lymphoma 2 (Bcl-2) downregulation and caspase-3 upregulation. The findings of the present study indicated that GAS5 may be a novel therapeutic target for IDD due to its pro-apoptotic effects.

Materials and methods
=====================

### Cell culture

Intervertebral disc-derived primary human NPCs were obtained from ScienCell Research Laboratories, Inc. (cat. no. 4800) ([@b20-mmr-19-03-2164],[@b21-mmr-19-03-2164]), and cultured in NPC medium (cat. no. 4801; both ScienCell Research Laboratories, Inc., San Diego, CA, USA) at 37°C in a humidified atmosphere containing 5% CO~2~. At \~80-90% confluence, cells were passaged at a ratio of \~1:2-3.

### Prediction of miR-155 targeting lncRNAs by TargetScan

A total of three miRNA target gene prediction software programs were compared, including TargetScan version 7.0 (<http://www.targetscan.org/>), PITA version 6 (<https://omictools.com/pita-tool>) and PicTar (<https://pictar.mdc-berlin.de/>); analysis with TargetScan was selected for its high sensitivity and accuracy in analyzing non-conserved domains ([@b22-mmr-19-03-2164],[@b23-mmr-19-03-2164]). The miRNAs targeting lncRNAs were screened based on the method of conserved seed pairing via TargetScan analysis; however, during the prediction of miRNA-targeted lncRNAs, the TargetScan Perl script was run by replacing the mRNA sequences with lncRNA sequences. In the present study, NPC apoptosis-associated lncRNAs were screened by searching the lncRNAs targeted by miR-155. miR-155 expression is decreased in the degenerative NP ([@b10-mmr-19-03-2164],[@b11-mmr-19-03-2164]); 866 upregulated lncRNAs were confirmed as subjects for analysis in the present study. Additionally, retrieval with TargetScan version 7.0, Ensembl Genome Browser (<http://asia.ensembl.org/index.html>), UCSC Genome Browser (<http://genome.ucsc.edu/>), and miRBase release 21 (<http://www.mirbase.org/>) further confirmed the sequence of 631 lncRNAs used for bioinformatics analysis.

### Transfection of miR-155 mimics

The sequence of mature hsa-miR-155-5p (MIMAT0000646) was retrieved from the miRBase database (<http://www.mirbase.org/>). Double-chain hsa-miR-155-5p and double-chain negative control (NC) RNA were designed and synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China). The synthesized hsa-miR-155-5p mimics were: Sense, 5′-UUAAUGCUAAUCGUGAUAGGGGU-3′ and antisense, 5′-CCCUAUCACGAUUAGCAUUAAUU-3′. The double-chain NC RNA sequences were: Sense, 5′-UUCUCCGAACGUGUCACGUTT-3′ and antisense, 5′-ACGUGACACGUUCGGAGAATT-3′. The day prior to transfection, NPCs were seeded into a 24-well plate at a density of 0.5×10^5^/well in 500 µl NPC medium. At \~70% confluence, NPCs were transfected with 1 µl double-chain hsa-miR-155-5p (20 µM) and double-chain NC RNA (20 µM), respectively, using Lipofectamine^®^ 2000 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). After 72 h of incubation at 37°C, the cells were assessed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) as described below.

### Lentivirus-mediated hsa-miR-155 overexpression

Lentivirus-mediated miR-155 overexpression reagents were ordered from Shanghai (Lingke) Biotechnology Co., Ltd. (Shanghai, China), Packaging 293T cells were transfected with plasmids comprised of pRsv-REV, pMDlg-pRRE, pMD2G and transfer vector: pLenO-GTP. The NPCs transfected miR-155 overexpression exhibited green fluorescence under fluorescence microscopy due to the element of pLenO-GTP expressing green fluorescence protein. Using fluorescence microscopy (magnification, ×40; Olympus IX73-DP80; Olympus Corporation, Tokyo, Japan), the efficiency of transduction was evaluated by calculating the percentage of green fluorescent protein-positive NPCs in 10 fields of view near the center of the culture vessel. The day prior to transduction, NPCs were seeded into a 6-well plate at a density of 5.0×10^5^/well in 2.5 ml NPC medium and incubated under a humidified atmosphere with 5% CO~2~ at 37°C. At \~60% confluence, NPCs were transduced with miR-155 or a NC at a multiplicity of infection (MOI) of 80. After 96 h post-incubation, total RNA was extracted and assessed via an lncRNA array as described below. The efficiency of transduction was determined successful when \>95% at 96 h after transduction.

### Human lncRNA plus mRNA array

Total RNA was extracted using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) from lentivirus-mediated miR-155 overexpression NPCs and NC groups. The purity and concentration, as determined by the optical density (OD) 260/OD280 ratio, was ≥1.90 with total RNA ≥1 µg per sample, which was assessed with a NanoDrop 1000 device (NanoDrop Technologies; Thermo Fisher Scientific, Pittsburgh, PA, USA). Denaturing formaldehyde agarose gel electrophoresis (percentage of 1.2%) demonstrated clear RNA bands, with 28S to 18S exceeding 2 bands and good RNA integrity (data not shown). Then, lncRNA array detection was performed by Beijing Capitalbio Technology Co., Ltd. (Beijing, China).

The Agilent human lncRNA + mRNA Array v4.0 (Agilent Technologies, Inc., Santa Clara, CA, USA) was used to detect lncRNAs in the present model system. Cy5 and Cy3 were used to label the molecule types on the same array at 37°C for 1.5 h and 70°C for 5 min, respectively. The Agilent array contained probes capable of detecting \~41,000 human lncRNAs and 34,000 human mRNAs, in a 4×180 K format. The array also contained 4,974 internal Agilent control probes. The experiments were performed according to the manufacturer\'s protocols and conducted twice. The fluorescent signals of Cy3 and Cy5 were obtained, and differentially expressed mRNAs and lncRNAs were screened, at a fold change cutoff of 2 and P\<0.05.

### Lentivirus-mediated GAS5 overexpression

Lentivirus-mediated GAS5 overexpression reagents were ordered from Lingke Biotechnology Co., Ltd., by using packaging 293T cells transfected with plasmids comprised of pRsv-REV, pMDlg-pRRE, pMD2G and transfer vector: pLenO-GTP. The NPCs with GAS5 overexpression exhibited green fluorescence for the element of pLenO-GTP expressing green fluorescence protein. NPCs were seeded into a 6-well plate at a density of 5.0×10^5^/well in 2.5 ml NPC medium and incubated for 24 h under a humidified atmosphere with 5% CO~2~ at 37°C. At \~60% confluence, NPCs were transduced with GAS5 (NR_002578.2; <http://www.ncbi.nlm.nih.gov/nuccore/NR_002578.2>) or NC (empty vector) at an MOI of 80. After 96 h post-incubation, GAS5 expression was assessed by RT-qPCR.

### RT-qPCR

Total RNA was extracted from NPCs using TRIzol reagent; the purity and quantity of RNA were assessed using a NanoDrop 1000 system. RT was performed on an ABI Veriti gradient PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) using a PrimeScript^™^ RT-PCR kit (Takara Bio, Inc., Otsu, Japan), the reaction conditions were: 30°C for 10 min, 42°C for 30 min and 72°C for 15 min. The following primers were used: Hsa-miR-155-5p forward, 5′-GGGGGTAATGCTAATCGTGAT-3′ and reverse, 5′-GTGCGTGTCGTGGAGTCG-3′; U6 forward, 5′-GCTTCGGCAGCACATATACTAAAAT-3′ and reverse, 5′-CGCTTCACGAATTTGCGTGTCAT-3′; lncRNA GAS5 sense, 5′-GCTTACTGCTTGAAAGGGTCT-3′ and antisense, 5′-CACTGGGAGGCTGAGGAT-3′; β-actin sense, 5′-GCACCACACCTTCTACAATGAG-3′ and antisense, 5′-ACAGCCTGGATAGCAACGT-3′. qPCR was performed on a Light Cycler 480 II RT-PCR system (Roche Diagnostics, Indianapolis, IN, USA) with SYBR-Green I (Takara Bio, Inc.). The reaction conditions were: 95°C for 30 sec, 95°C for 5 sec and 60°C for 30 sec (40 cycles). Each experiment was repeated three times, the relative mRNA expression levels were evaluated by the 2^−ΔΔCq^ method ([@b24-mmr-19-03-2164]).

### Cell apoptosis detection by flow cytometry

NPCs exhibited green fluorescence following lentiviral transduction, Annexin V-allophycocyanin (eBioscience; Thermo Fisher Scientific, Inc.) was used for cytomembrane staining (NPCs were stained for 25 min at room temperature without light), and propidium iodide (eBioscience; Thermo Fisher Scientific, Inc.) was used for nuclear staining (NPCs were stained for 5 min at room temperature). Subsequently, the transfection efficiency and apoptosis of NPCs were assessed using a CytoFLEX flow cytometer (Beckman Coulter, Inc., Brea, Ca, USA). Data were analyzed via the FlowJo 7.6.1 software (FlowJo LLC, Ashland, OR, USA). NPCs stained with Annexin V-allophycocyanin without propidium iodide were considered as early apoptotic NPCs, and the early apoptosis rate was determined by calculating the percentage of NPCs in the lower right quadrant of the scatter diagram.

### Western blotting

Total protein from NPCs was extracted following lysis with radioimmunoprecipitation assay buffer (Thermo Fisher Scientific, Inc.), and quantified with a Bicinchoninic Acid protein assay. Then, 40 µg total protein from NPCs were loaded and separated by 15% SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Merck KGaA, Darmstadt, Germany). Following blocking with 5% bovine serum albumin for 2 h at room temperature, rabbit anti-human caspase-3, rabbit anti-human Bcl-2 and mouse anti-human β-actin polyclonal antibodies (cat. nos. 9665, 2870 and 3700; 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA) were added respectively overnight at 4°C. Then, membranes were washed with tris-buffered saline with 0.1% Tween-20 and incubated with anti-rabbit secondary antibodies conjugated to horseradish peroxidase (cat. no. 7074; 1:1,000) for rabbit anti-human caspase-3 and rabbit anti-human Bcl-2 antibodies and anti-mouse secondary antibodies conjugated to horseradish peroxidase for mouse anti-human β-actin antibody (cat. no. 7076; 1:1,000; both Cell Signaling Technology, Inc.). Finally, the membranes were developed with an enhanced chemiluminescence reagent (Pierce^™^ ECL Western Blotting Substrate, Pierce; Thermo Fisher Scientific, Inc.); protein bands were imaged under a FluorChem FC2 visualizer (Alpha Innotech, San Leandro, CA, USA).

### Statistical analysis

SSPSS 19.0 (IBM Corp., Armonk, NY, USA) was used for data analysis. Data were presented as the mean ± standard deviation from three independent experiments performed in triplicate. Comparisons between groups were conducted using an Independent Samples t-test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Overexpression of miR-155 in NPCs

NPCs were transduced with lentiviral vectors ([Fig. 1](#f1-mmr-19-03-2164){ref-type="fig"}). Under fluorescence microscopy, the transduction efficiencies were determined to be \>95% ([Fig. 1A](#f1-mmr-19-03-2164){ref-type="fig"}). In addition, miR-155 expression levels in lentiviral-transduced NPCs were assessed by RT-qPCR; significantly higher miR-155 expression levels were detected in NPCs transduced with miR-155 compared with the control group ([Fig. 1B](#f1-mmr-19-03-2164){ref-type="fig"}). These findings indicated a highly efficient and successful overexpression of miR-155 in transduced NPCs.

### Prediction of miR-155 targeted lncRNAs

TargetScan data analysis revealed that among the 631 upregulated lncRNAs with defined sequences, there were 148 differentially expressed lncRNAs with 178 hsa-miR-155-5p binding sites in total (data not shown). Among these, NR_002819 with 8,707 nucleotides, which included 6 hsa-miR-155-5p binding sites; ENST00000511037 and NR_027451 contained 1801 and 5343 nucleotides, respectively, which included 5 hsa-miR-155-5p binding sites. In addition, there were 19 lncRNAs with 2 hsa-miR-155-5p binding sites and 126 lncRNAs containing 1 hsa-miR-155-5p binding site. Furthermore, NR_002578 was observed to contain a hsa-miR-155-5p binding site and was also predicted to be a target of miR-155. Additionally, a literature review indicated that NR_002578 is an lncRNA transcribed from GAS5 and is highly expressed in NPCs of the degenerative intervertebral disc ([@b12-mmr-19-03-2164]), with a tumor suppressor role in a variety of tumors, promoting tumor cell apoptosis ([@b19-mmr-19-03-2164]).

### miR-155 overexpression inhibits GAS5 expression in NPCs

After \~72 h following miR-155 mimics transfection into NPCs ([Fig. 2A](#f2-mmr-19-03-2164){ref-type="fig"}), the overall GAS5 expression levels were determined. The results revealed significantly lower expression levels of GAS5 compared with the NC group ([Fig. 2B](#f2-mmr-19-03-2164){ref-type="fig"}).

### LncRNA array analysis in NPCs overexpressing miR-155

LncRNA array analysis revealed 721 differentially expressed lncRNAs following transduction with miR-155 lentiviruses, 492 upregulated and 229 downregulated lncRNAs, respectively ([Fig. 3](#f3-mmr-19-03-2164){ref-type="fig"}). A total of 18 GAS5 transcripts were detected, and each individual transcript showed downregulated expression ([Table I](#tI-mmr-19-03-2164){ref-type="table"}); however, the fold changes of each individual transcript did not exhibit significance. The results suggested that different overexpression mehtods using mimics or lentiviruses may affect GAS5 expression.

### Effects of GAS5 overexpression on cell apoptosis and apoptosis-associated proteins in NPCs

The transduction efficiency was determined to be 95% at 96 h post-transduction ([Fig. 4A](#f4-mmr-19-03-2164){ref-type="fig"}), and classic bleb-like protuberances were observed during cell growth ([Fig. 4B](#f4-mmr-19-03-2164){ref-type="fig"}). At 96 h following lentiviral transduction, GAS5 expression levels were significantly increased compared with the NC group (P\<0.05; [Fig. 4C](#f4-mmr-19-03-2164){ref-type="fig"}).

As detected by flow cytometry, the early apoptosis rates were 35.4±1.86 and 42.6±2.23% in the NC and GAS5 overexpression groups, respectively, which indicated that GAS5 overexpression induced early apoptosis of NPCs (P\<0.05; [Fig. 5A](#f5-mmr-19-03-2164){ref-type="fig"}). The expression levels of the two apoptosis-associated proteins, caspase-3 and Bcl-2, which were determined by western blotting, were notably upregulated and downregulated, respectively, when GAS5 was overexpressed in NPCs ([Fig. 5B](#f5-mmr-19-03-2164){ref-type="fig"}).

Discussion
==========

Numerous lncRNAs are differentially expressed in NP tissues, which suggests the important roles of lncRNAs in the development of IDD ([@b12-mmr-19-03-2164],[@b13-mmr-19-03-2164]). Previous studies have preliminarily investigated several functional mechanisms of lncRNA GAS5, mostly in neoplastic and osteoarthritis degenerative diseases. Song *et al* ([@b25-mmr-19-03-2164]) reported that GAS5 overexpression increased the expression levels of MMP-2, MMP-3, MMP-9, MMP-13 and A disintegrin and metalloproteinase with thrombospondin motifs-4 in cartilage cells, further inducing apoptosis and inhibiting autophagy. These effects may be inhibited by miR-21, which specifically targets GAS5. Li *et al* ([@b26-mmr-19-03-2164]) demonstrated that GAS5 ameliorated LPS-induced inflammatory injury in ATDC5 chondrocytes by inhibiting the nuclear factor-κB and Notch signaling pathways. Additionally, the roles of GAS5 lncRNA in tumor growth inhibition were investigated in several studies. Guo *et al* ([@b27-mmr-19-03-2164]) reported that GAS5 significantly increased the expression of phosphatase and tensin homolog via miR-103 inhibition, promoting the apoptosis of endometrial cancer cells. Zhao *et al* ([@b28-mmr-19-03-2164]) also indicated that GAS5 inhibited glioma cell growth by directly targeting and inhibiting miR-222; however, to the best of our knowledge, no studies on cartilage tumors have been conducted.

In the present study, GAS5 was predicted as a target of miR-155 by lncRNA-miRNA regulatory network analysis and the overall expression of GAS5 was observed to be significantly reduced following the transfection of NPCs with miR-155 mimics. Furthermore, array analysis revealed that each detected GAS5 transcript exhibited a downregulated expression profile following NPC transduction with miR-155 lentiviruses. These findings indicated a negative regulatory effect of miR-155 on GAS5 expression in NPCs; however, the underlying regulatory mechanism requires further investigation. For example, a dual-luciferase reporter gene assay may demonstrate the interaction between GAS5 with miR-155 and an RNA pull-down assay may detect the target proteins of GAS5; such investigations may clarify the functions of GAS5.

Studies on a variety of cancers demonstrated that GAS5 was a tumor suppressor, and inhibited proliferation and promoted apoptosis; GAS5 was proposed to be involved in numerous key regulatory pathways associated cell survival ([@b29-mmr-19-03-2164]--[@b31-mmr-19-03-2164]). Therefore, the function of GAS5 in determining cell survival or death has attracted increasing attention, particularly in cancer research ([@b19-mmr-19-03-2164]). Consistently, a similar effect was observed in NPCs, as GAS5 overexpression promoted NPC apoptosis *in vitro*.

The three main apoptotic pathways (mitochondrial, death receptor and endoplasmic reticulum stress pathways) are involved in different stages of IDD development ([@b32-mmr-19-03-2164]). Among them, the mitochondrial pathway serves a major role in moderate to severe stages of IDD ([@b33-mmr-19-03-2164],[@b34-mmr-19-03-2164]). The release of apoptosis-associated molecules, including cytochrome *c* (Cyt *c*), apoptosis-inducing factor, Endo G and Smac in mitochondria, is initiated by stress and apoptosis signaling; Cyt *c* then binds apoptotic protease activating factor-1 and caspase-9 zymogen forming the apoptosome, and activates the caspase-3 cascade that ultimately leads to apoptosis ([@b35-mmr-19-03-2164]). Bcl-2 and caspase proteases are two protein families with conserved evolution. Bcl-2 protein controls mitochondrial integrity and inhibits Cyt *c* release, therefore inhibiting apoptosis ([@b35-mmr-19-03-2164]). In addition, caspases initiate and execute the process of apoptosis; among them, caspases-3, 6, and 7 execute the process of apoptosis ([@b35-mmr-19-03-2164]). For instance, *in vitro* silencing of caspase-3 suppressed the apoptosis of NPCs induced by mechanical overload, further inhibiting IDD ([@b36-mmr-19-03-2164]). In the present study, the effect of GAS5 on NPC apoptosis was reported, and the underlying mechanism was investigated. As aforementioned, GAS5 overexpression downregulated the expression of Bcl-2 and upregulated that of caspase-3, therefore promoting NPC apoptosis. Of note, GAS5 involvement in mitochondrial apoptosis has been previously reported; by directly targeting miR-222, GAS5 could indirectly inhibit Bcl-2 expression in glioma cells ([@b28-mmr-19-03-2164]). In addition, GAS5 promoted the apoptosis of ovarian cancer cells via caspase-3 and caspase-9 upregulation ([@b37-mmr-19-03-2164]). Additionally, the oncogenesis of some cartilage tumors, including chondrosarcoma and chondroblastic osteosarcoma, has exhibited a high correlation with the mitochondrial pathway of apoptosis ([@b38-mmr-19-03-2164]--[@b40-mmr-19-03-2164]). Future studies on these tumors are required to further verify the function of GAS5 in mitochondrial apoptosis, providing that GAS5, as a tumor suppressor, may inhibit tumor growth and proliferation.

Biomolecular therapy, cell therapy, tissue-engineered construction and annulus fibrosus repair are novel strategies for treating IDD ([@b41-mmr-19-03-2164]). Using biomolecules, including recombinant genes, proteins or platelet-rich plasma, to adjust cellular metabolism and extracellular matrix regeneration, early degenerated disks with sufficient viable NPCs can be treated to mitigate the progression of disc degeneration ([@b42-mmr-19-03-2164]). Midstage degeneration, characterized by fewer active cells, can be treated with cell implantations, including stem cells or allogeneic NPCs to meet the demand of the disk for active NPCs and reverse the degenerative process ([@b43-mmr-19-03-2164],[@b44-mmr-19-03-2164]). Accordingly, with a thorough understanding of GAS5 functions, ultrasound- or computed tomography-guided injection of GAS5-silenced NPCs, or lentivirus-mediated GAS5 knockdown may improve the precision and efficiency of IDD treatment.

There were several limitations of the present study. Firstly, GAS5 overexpression in degenerative NP, though demonstrated in a previous microarray study ([@b12-mmr-19-03-2164]), requires further clinical investigation. In addition, RNA sample extraction in severely degenerated NP is yet to be resolved. The downregulation of GAS5 may have more clinical value in the treatment of IDD, while the present study only conducted overexpression. Additionally, the inter-regulatory dependence of the mechanism investigated in the present study requires further study.

In conclusion, GAS5 overexpression resulted in increased apoptosis in primary NPCs from the human intervertebral disc via Bcl-2 downregulation and caspase-3 upregulation. GAS5, predicted to be a target of miR-155 by TargetScan analysis, was proposed to be downregulated by miR-155 overexpression. The findings of the present study may provide novel insight into the role of GAS5 in IDD pathogenesis and contribute to developments in the treatment of IDD via biomolecular or cellular therapies.
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![Expression of miR-155 in nucleus pulposus cells following transduction with miR-155 OE lentiviruses. (A) Transduction efficiencies of green fluorescent protein-positive cells was determined successful when \>95% at 96 h after transduction. Magnification, ×40. (B) miR-155 expression levels determined by reverse transcription-quantitative polymerase chain reaction at 96 h following transduction. Data are presented as the mean ± standard error of the mean from three independent experiments performed in triplicate. \*P\<0.05 vs. NC group. miR, microRNA; NC, negative control; OE, overexpression.](MMR-19-03-2164-g00){#f1-mmr-19-03-2164}

![GAS5 expression levels after 72 h following nucleus pulposus cell transfection with miR-155 mimics. (A) miR-155 transfection was confirmed via reverse transcription-quantitative polymerase chain reaction. Data are presented as the mean ± standard error of the mean from three independent experiments performed in triplicate. \*P\<0.05 vs. NC group. (B) GAS5 expression levels were determined following transfection with miR-155 mimics. Data are presented as the mean ± standard deviation from three independent experiments performed in triplicate. \*P\<0.05 vs. NC group. GAS5, growth arrest-specific transcript 5; miR, microRNA; NC, negative control.](MMR-19-03-2164-g01){#f2-mmr-19-03-2164}

![LncRNA array analysis. A total of 492 lncRNAs were upregulated and 229 lncRNAs were downregulated. (A) Cluster analysis of differentially expressed lncRNAs; (B) scatter plot of differentially expressed lncRNAs and (C) volcano plot of differentially expressed lncRNAs. LncRNA, long noncoding RNA; miR, microRNA; NC, negative control; OE, overexpression.](MMR-19-03-2164-g02){#f3-mmr-19-03-2164}

![GAS5 expression levels following the transduction of NPCs with lentivirus containing GAS5 lncRNA. (A) Efficiency obtained 96 h following transduction. Magnification, ×40. (B) Protuberances of NPCs observed during cell growth. Magnification, ×100. (C) GAS5 expression levels assessed by reverse transcription-quantitative polymerase chain reaction at 96 h following transduction. Data are presented mean ± standard deviation from three independent experiments performed in triplicate. \*P\<0.05 vs. NC group. GAS5, growth arrest-specific transcript 5; lncRNA, long noncoding RNA; NC, negative control; NPCs, nucleus pulposus cells; OE, overexpression.](MMR-19-03-2164-g03){#f4-mmr-19-03-2164}

![Effects of GAS5 OE on apoptosis and apoptosis-associated protein expression levels in nucleus pulposus cells. (A) Cell apoptosis was assessed by flow cytometry via Annexin V-APC/PI staining at 96 h following transduction; (B) caspase-3 and Bcl-2 protein expression levels were determined by western blotting at 96 h following transduction, with β-actin as a loading control. Data are presented as the mean ± standard deviation from three independent experiments. \*P\<0.05 vs. NC group. APC, allophycocyanin; Bcl-2, B-cell lymphoma 2; GAS5, growth arrest-specific transcript 5; lncRNA, long noncoding RNA; NC, negative control; OE, overexpression; PI, propidium, iodide.](MMR-19-03-2164-g04){#f5-mmr-19-03-2164}

###### 

Expression of 29 transcripts of GAS5 lncRNA when overexpressing miR-155 in NPCs.

  Name       Transcript ID     Probe                                                Expression      P-value   Fold change
  ---------- ----------------- ---------------------------------------------------- --------------- --------- -------------
  GAS5-001   ENST00000450589   --^[a](#tfn1-mmr-19-03-2164){ref-type="table-fn"}^   --              --        --
  GAS5-002   ENST00000431268   p28959                                               Downregulated   0.38      1.12
  GAS5-003   ENST00000448718   --                                                   --              --        --
  GAS5-004   ENST00000436656   p33995_v4                                            Downregulated   0.26      1.17
  GAS5-005   ENST00000458220   p547                                                 Downregulated   --        --
  GAS5-006   ENST00000421068   p545                                                 Downregulated   0.76      1.08
  GAS5-007   ENST00000456293   p543                                                 Downregulated   0.43      1.15
  GAS5-008   ENST00000449289   --                                                   --              --        --
  GAS5-009   ENST00000455838   p541                                                 Downregulated   0.45      1.13
  GAS5-010   ENST00000449589   --                                                   --              --        --
  GAS5-011   ENST00000443799   p544                                                 Downregulated   0.66      1.08
  GAS5-012   ENST00000416952   p542                                                 Downregulated   0.49      1.12
  GAS5-013   ENST00000452197   --                                                   --              --        --
  GAS5-014   ENST00000454068   p33998_v4                                            Downregulated   0.19      1.36
  GAS5-015   ENST00000451607   p34000_v4                                            Downregulated   0.09      1.35
  GAS5-016   ENST00000432536   p34001_v4                                            Downregulated   0.20      1.31
  GAS5-017   ENST00000436285   --                                                   --              --        --
  GAS5-018   ENST00000442067   p540                                                 Downregulated   0.07      1.53
  GAS5-019   ENST00000422183   p33997_v4                                            Downregulated   0.30      1.24
  GAS5-020   ENST00000425771   p546                                                 Downregulated   0.19      1.27
  GAS5-021   ENST00000422008   p539                                                 Downregulated   0.02      1.77
  GAS5-022   ENST00000412059   --                                                   --              --        --
  GAS5-023   ENST00000422207   --                                                   --              --        --
  GAS5-024   ENST00000434796   p33999_v4                                            Downregulated   0.27      1.21
  GAS5-025   ENST00000444470   --                                                   --              --        --
  GAS5-026   ENST00000454813   p538                                                 Downregulated   0.36      1.13
  GAS5-027   ENST00000430245   p33996_v4                                            Downregulated   0.32      1.18
  GAS5-028   ENST00000414075   --                                                   --              --        --
  GAS5-029   ENST00000456812   --                                                   --              --        --

Not applicable. NPC, nucleus pulposus cell; GAS5, growth arrest-specific transcript 5; lncRNAs, long noncoding RNAs.
